198 results on '"Lito, Piro"'
Search Results
2. RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax
3. Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
4. In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma
5. Pan-KRAS inhibitor disables oncogenic signalling and tumour growth
6. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
7. Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
8. Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation.
9. Preclinical Evaluation of [124I]-Sotorasib for the Imaging of Kirsten Rat Sarcoma G12C Mutant Tumors.
10. Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers
11. Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced KRAS G12C-Mutant Non–Small Cell Lung Cancer
12. The KRYSTAL-1 study of adagrasib — a new trial for KRASG12C-mutated non-small-cell lung cancer
13. Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in Patients
14. Long-term benefit of sotorasib in patients with KRAS G12C–mutated non–small-cell lung cancer: plain language summary
15. Modeling lung adenocarcinoma metastases using patient-derived organoids
16. Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
17. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
18. Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer
19. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non–Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100
20. Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes
21. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
22. Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer.
23. Supplementary Data from The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
24. Data from The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
25. Supplementary Figures from KRASG12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma
26. Supplementary Data Table 2 from Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation
27. Supplementary Tables from KRASG12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma
28. Supplemental Tables 1-4, Supplemental Figures 1-2 from Effects of Co-occurring Genomic Alterations on Outcomes in Patients with KRAS-Mutant Non–Small Cell Lung Cancer
29. Supplementary Data Table 4 from Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation
30. Supplementary Data Table 1 from Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation
31. Supplementary Data Table 5 from Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation
32. Supplementary Figure Legends from Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation
33. Supplementary Data S1-S3 from Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation
34. Supplementary Data Table 3 from Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation
35. A treatment strategy for KRAS-driven tumors
36. Disruption of CRAF-Mediated MEK Activation Is Required for Effective MEK Inhibition in KRAS Mutant Tumors
37. Insights into how adeno-squamous transition drives KRAS inhibitor resistance.
38. Expanding the Arsenal of Clinically Active KRAS G12C Inhibitors
39. Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas
40. Clinicopathologic characterization of ERK2 E322K mutation in solid tumors: Implications for treatment and drug development.
41. Phase 1 Clinical Trial of Trametinib and Ponatinib in Patients With NSCLC Harboring KRAS Mutations
42. With one eye on the future
43. CANCER THERAPEUTICS: Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism
44. Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers
45. Diverse alterations associated with resistance to KRAS(G12C) inhibition
46. Sprouty 2 Regulates DNA Damage-induced Apoptosis in Ras-transformed Human Fibroblasts
47. Gastroenteropancreatic Neuroendocrine Tumors in Patients With HIV Infection: A Trans-Atlantic Series
48. Tumor adaptation and resistance to RAF inhibitors
49. The G protein signaling regulator RGS3 enhances the GTPase activity of KRAS
50. Evidence That Sprouty 2 Is Necessary for Sarcoma Formation by H-Ras Oncogene-transformed Human Fibroblasts
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.